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Abstract
Objective: Little information is available concerning the relationships 
between clarithromycin resistance and virulence marker genes (iceA, cagA 
and vacA) in Helicobacter pylori isolated in Taiwan. The aim of this study 
was to evaluate the possible association between clarithromycin resis-
tance and genotypes of the virulence markers on clarithromycin-resistant 
H. pylori isolates obtained in eastern Taiwan.
Materials and Methods: The genotypes of the virulence marker genes 
(iceA, cagA and vacA) were analyzed by PCR, and the 23S rDNA region 
from 18 clarithromycin-resistant clinical isolates of H. pylori was amplified 
by PCR and sequenced.
Results: Point mutations were found to occur in all isolates. Two isolates 
had A2143G, six had T2182C, one had C2227T, six had A2143G plus 
T2182C, and three had heterozygous alleles. The latter included a wild-
type allele (A2143) plus (i) an A2143G, (ii) an A2143G plus an A2223G, 
and (iii) an A2143G plus a T2182C. The prevalence of the marker genes 
cagA, iceA1, iceA2, and both iceA1 and iceA2, in the isolates was 95.5%, 
66.9%, 7.5%, and 25.6%, respectively. The vacAs1 allele was detected in 
all isolates, whereas the m1 and m2 alleles were found in 44.4% and 
55.6% of the isolates, respectively.
Conclusion: There were no significant associations between clarithromy-
cin resistance and the presence of the cagA gene, vacA allele mosaicism, 
and the iceA genotypes. The most notable finding of our study was that 
the C2227T single mutation in 23S rDNA could also be related to the high 
clarithromycin minimal inhibitory concentrations in clinical isolates from 
eastern Taiwan. [Tzu Chi Med J 2009;21(2):123–128]
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1. Introduction
Helicobacter pylori may be the most common infec-
tion in the world. The prevalence of this infection is 
higher in developing countries than in the USA and 
Western Europe [1,2]. Infection by this organism has 
been documented as an etiologic factor in chronic 
gastritis, peptic ulcer disease, gastric carcinoma, and 
lymphoma [3–7]. Successful treatment of H. pylori 
infection not only results in eradication of the patho-
gen, but may also cure and prevent the associated 
diseases. However, drug resistance to this organism 
reduces the success rates substantially.
The prevalence rate of antimicrobial resistance to 
H. pylori varies with geographical regions. In Taiwan, 
varied rates of resistance have been reported includ-
ing 13.5% to clarithromycin, 36.1% to amoxicillin, and 
52% versus 32% to metronidazole in the eastern and 
western parts of the country, while almost all H. pylori 
strains are susceptible to tetracycline [8]. Therefore, 
the most widely used primary regimen for H. pylori 
eradication in eastern Taiwan is triple therapy with 
clarithromycin, tetracycline, and a proton-pump inhibi-
tor. Unfortunately, the clarithromycin resistance rate 
has begun to increase recently in eastern Taiwan.
Clarithromycin resistance has been associated with 
point mutations in the peptidyltransferase region en-
coded in domain V of the H. pylori 23S ribosomal 
DNA (rDNA) gene, conferring an altered binding tar-
get [9,10]. H. pylori contains two copies of the 23S 
rDNA gene, and the two most common mutations 
are A  G transitions at positions 2142 or 2143 in 
the gene [9–11]. Other less frequent mutations, such 
as A2115G, G2141A, A2142C, A2144T, T2182C and 
T2717C, have also been reported [10,12–15]. Distri-
bution of these mutations varies geographically. In 
addition, the genetic diversity has clinical significance 
because there are strains with markers of enhanced 
virulence.
Patients carrying strains containing cagA or hav-
ing the gene that is induced on contact (iceA1) and 
vacAs1m1 alleles are at an increased risk of gastric-
related diseases [16,17]. CagA is the marker for pres-
ence of the pathogenicity island (Cag PAI), which is 
the most studied putative virulence factor [18]. VacA 
encodes a vacuolating toxin that causes target cell de-
generation by interfering with intracellular membrane 
fusion. Allelic variation of the signal sequence region 
(s1, s2) and of the mid-region (m1, m2) mosaic com-
bination is related to the production of vacuolating 
cytotoxin [19]. The iceA gene, induced by contact 
with gastric epithelial cells, has two main allelic vari-
ants (iceA1 and iceA2) and only the iceA1-carrying 
strain has been reported to be associated with a 
more severe clinical outcome [16,17]. A strong asso-
ciation between clarithromycin resistance and pres-
ence of iceA1, cagA and the vacAs1m2 allele has 
been reported [20–23]. However, molecular basis has 
not been established for the association between 
antibiotic resistance and bacterial genetic patterns. 
In this study, we analyzed the iceA, cagA and vacA 
status and evaluated the possible association between 
clarithromycin resis tance and genotypes of the viru-
lence markers on 18 clarithromycin-resistant H. pylori 
isolates obtained in eastern Taiwan.
2. Materials and methods
2.1. Bacterial strains
The 133 clinical H. pylori isolates obtained from 
gastric biopsy specimens from patients before treat-
ment have been described [8]. They were stored at 
−80°C in brain heart infusion broth containing 30% 
glycerol, recovered from frozen stocks and used 
in this study. The clarithromycin-sensitive H. pylori 
NCTC 11637 (originally from the American Type 
Culture Collection as ATCC 43504) was used as the 
reference strain.
2.2. DNA extraction
Genomic DNA was isolated from H. pylori isolates by 
phenol/chloroform extraction and ethanol precipita-
tion. Genomic DNA were resuspended in an appro-
priate volume of sterile deionized water and stored 
at −20°C until used.
2.3. PCR amplification of lspA-glmM genes 
and restriction fragment length 
polymorphism (RFLP)
For stain verification, we performed PCR-RFLP for 
lspA-glmM, a conserved gene formerly known as 
ureCD. Primers used for PCR amplification had the 
same nucleotide sequences as previously published 
ones, 5-TGGGACTGATGGCGTGAGGG-3 and 5-AT-
CATGACATCAGCGAAGTTAAAAATGG-3, which ampli-
fied a 1720-bp product [24]. Amplifications were 
performed in a model 2700 Perkin–Elmer thermal 
cycler (Perkin–Elmer Corp., Norwalk, CO, USA) using 
10 ng of H. pylori DNA, 0.5 units of Taq DNA polymer-
ase, 1X PCR buffer (Roche Molecular Biochemicals, 
Indianapolis, IN, USA), 1.5 mM MgCl2, 100 nM of each 
primer, and 200 μM of each dNTP (Amersham 
Pharmacia Biotech, Piscataway, NJ, USA). The cycling 
program included an initial denaturation step at 94°C 
for 2 minutes, followed by 35 cycles with the follow-
ing profiles: 1 minute at 94°C, 1 minute at 50°C, and 
2 minutes at 72°C. The PCR products were electro-
phoresed in agarose gel, followed by HhaI digestion 
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(3 hours at 37°C) in the buffer recommended by the 
supplier (New England Biolabs, Inc., Beverly, MA, USA). 
The digests were electrophoresed in 5% polyacryla-
mide gel, stained with ethidium bromide and photo-
graphed. Each H. pylori isolate was thus characterized 
by the banding patterns.
2.4. Analysis of mutations associated with 
clarithromycin resistance
To detect resistance to clarithromycin in H. pylori 
isolates, point mutations of the 23S rDNA gene were 
examined by PCR-RFLP as described previously [25]. 
Briefly, DNA extracted from H. pylori isolates was sub-
jected to PCR with primers extending from position 
2031 to 2050 (forward, 5-ATCGCTGATACCGTCGTGCC-
3) and from 2726 to 2706 (reverse, 5-CTTTTTAG-
GAGCGACCGCCCC-3) (GenBank accession number 
U27270). The amplified 696-bp DNA fragments were 
digested with MboII and BsaI (New England Biolabs, 
Inc.), allowing for detection of the A2142G and A2143G 
mutations, respectively. The restriction products were 
analyzed by electrophoresis in 2% agarose gel. In ad-
dition, amplicons were purified with a Gel/PCR DNA 
Fragments Extraction Kit (Geneaid Biotech Ltd., Taipei, 
Taiwan) and the same primers for the PCR reaction 
were used for sequencing. Sequencing was performed 
on both strands with an automated DNA sequencer 
(ABI PRISM 3730, Applied BioSystems, Darmstadt, 
Germany).
2.5. Detection of cagA, iceA, and vacA 
genotypes by PCR
The genotypes of the cagA, iceA, and vacA genes 
were determined via PCR according to a previously 
described method [17].
2.6. Statistical analyses
Statistical analyses were performed using the Pearson 
χ2 test and Fisher’s exact test. A p value of ≤ 0.05 was 
accepted as statistically significant.
3. Results
3.1. PCR-RFLP fingerprinting
The analysis of the DNA fingerprinting obtained 
through the PCR-RFLP for lspA-glmM, a conserved 
gene formerly known as ureCD, confirmed the total 
heterogeneity among these isolates from different 
individuals (data not shown).
3.2. Distribution of the cagA gene, iceA 
genotype and vacA mosaicism
The cagA, iceA, and vacA (s and m region) genotypes 
were assessed in the 133 H. pylori infected patients 
(mean age, 51.2 ± 14.9 years; 55 men). Among these 
patients, 50 (23 men and 27 women; mean age, 
56 ± 12 years) had peptic ulcer disease (PU, 37.6%), 
and 83 (32 men and 51 women; mean age, 49 ± 16 
years) had chronic gastritis (CG, 62.4%). Among these 
133 isolates, 127 were found to have cagA (95.5%; 
PU, 48; CG, 79), only 89 had iceA1 (66.9%; PU, 31; 
CG, 58), 10 had iceA2 (7.5%; PU, 5; CG, 5), 34 pos-
sessed both iceA1 and iceA2 (25.6%; PU, 13; CG, 21), 
whereas all of the isolates had the vacAs1 allele, 59 
cases had m1 allele (44.4%; PU, 24; CG, 35), and 74 
isolates had m2 (55.6%; PU, 25; CG, 49) (Table 1).
3.3. Mutation sites associated with 
clarithromycin resistance
Among the 133 isolates, 18 (13.5%) showed clarithro-
mycin resistance. The distribution of minimal inhibitory 
concentrations (MIC) in the 18 clarithromycin-resistant 
strains was 1 μg/mL in one of the isolates, 2 μg/mL in 
two, 3 μg/mL in one, 8 μg/mL in two, 16 μg/mL in one, 
48 μg/mL in one, and ≥ 256 μg/mL in 10, as described 
previously [8]. Analysis of the 23S rDNA gene muta-
tion by PCR-RFLP was performed for all 18 isolates, 
which were judged to be resistant to clarithromycin 
by the E-test (AB Biodisk, Solna, Sweden). A2143G 
mutations were detected in eight (44.4%) resistant 
isolates; however, the restriction cleavage was incom-
plete in three amplicons (Fig. 1). None of these re-
sistant isolates was cleaved by MboII, indicating that 
there was no A2142G mutation type in these strains. 
On sequencing the PCR amplicons of these 18 strains, 
two were shown to have a point mutation of A to G at 
position 2143 (A2143G), six had a T to C mutation 
at position 2182 (T2182C), one had a C to T mutation 
at position 2227 (C2227T), and six had an A2143G 
transition and an additional T2182C mutation. Fur-
thermore, sequencing of the fragments from individ-
ual colonies showed that three of the isolates with 
an incomplete pattern of BsaI digestion had hetero-
zygous genotypes: a wild-type allele (A2143) plus 
(i) an A2143G, (ii) an A2143G plus an A2223G, and 
(iii) an A2143G plus a T2182C (Table 2). None of the 
fragments from the sensitive isolates were cleaved 
by either the BsaI or MboII enzyme.
MIC values of the T2182C mutants were relatively 
high (≥ 256 μg/mL), except for one isolate (1 μg/mL), 
and those of the A2143G single mutants ranged from 
2 to 48 μg/mL. However, MICs of the T2182C and 
A2143G double mutants were from 3 to ≥ 256 μg/mL 
(Table 2).
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3.4. Genotype variations and 
clarithromycin resistance
Analysis of genotypes of the virulence factors (cagA 
status, iceA and vacA alleles) related to clarithromy-
cin resistance revealed that all of the clarithromycin 
resistant isolates were cagA positive, and most of 
them were of the iceA1 genotype (13/18; 72.2%). The 
prevalence of both the vacAm1 allele (41.7% vs. 
61.1%; p = 0.119) and m2 allele (58.3% vs. 38.9%; 
p = 0.125) did not significantly differ between suscep-
tible and resistant strains.
4. Discussion
Clarithromycin is the second most widely used anti-
biotic in H. pylori-infected patients, so resistance 
is a prime concern for physicians. The resistance 
rates vary geographically. For example, occurrence 
ranges from 9.9% to 43.5% in Europe [26], and is 
less than 4% in Canada [27], 10–15% in the USA [28], 
and 8–17% in Iran and Israel [29,30]. However, the 
M 1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19
517 bp
7
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179 bp
Fig. 1 — Representative electrophoretogram of BsaI-restriction profiles of the 696-bp 23S rDNA fragments which were 
amplified by PCR from clarithromycin-resistant H. pylori isolates. Lane M: DNA size markers. Lanes 1–7: with one 
517-bp and one 179-bp product which means lack of a restriction site at nt 2143. Lanes 8–16: each with a 300-, 217- 
and 179-bp product indicating an A to G mutation at position 2143. Lanes 17–19: with 4 fragments (517, 300, 217 and 
179 bp) which represent a heterozygous condition where one 23S rDNA allele is of the wild-type genotype (A2143) and 
the other has the mutant genotype (A2143G).
Table 2 — Minimal inhibitory concentrations (MIC) 
and mutation profiles of the clarithromycin-resistant 
Helicobacter pylori isolates
Isolate Clarithromycin MIC (μg/mL) Mutation sites
HP39 ≥ 256 T2182C
HP55 ≥ 256 T2182C
HP157 ≥ 256 T2182C
HP181 ≥ 256 A2143G, T2182C
HP187  1 T2182C
HP260 12 A2143G, T2182C
HP263 ≥ 256 A2143G*, A2223G
HP272 ≥ 256 T2182C
HP322  2 A2143G
HP324 ≥ 256 A2143G, T2182C
HP355 48 A2143G
HP368  3 A2143G, T2182C
A444  2 A2143G*
A472 ≥ 256 A2143G*, T2182C
A480  8 A2143G, T2182C
A504  8 A2143G, T2182C
A546 ≥ 256 C2227T
A1349 ≥ 256 T2182C
*With a heterozygous condition where one 23S rDNA allele was of the 
wild-type genotype (A2143) and the other was of the mutant geno-
type (A2143G), as revealed by PCR-RFLP and sequence analysis.
Table 1 — Distribution of genotypes among the 133 Helicobacter pylori isolates from patients in Eastern Taiwan
 From patients with  From patients with 
Genotype
 chronic gastritis (n = 84) peptic ulcer (n = 49) 
Total (n = 133)
cagA    
 Positive 79 48 127
 Negative  5  1  6
vacAs1   
 m1 35 24  59
 m2 49 25  74
iceA   
 1 58 31  89
 2  5  5  10
 1 + 2 21 13  34
n = number of isolates.
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prevalence rates in the far East are higher in Japan 
(11–12%) [31] and Taiwan (13.5% in the east, 18% in 
the northwest, 6% in the southwest) [8,32,33] than 
in Hong Kong (4.5%) [34] and Korea (5–6%) [35]. The 
mechanism of H. pylori resistance to clarithromycin 
was first shown to be caused by a single point muta-
tion within domain V of 23S rDNA (A to G transition) 
[9]. Other mutation points were also reported, such 
as A2115G, G2141A, A2142C or G or T, A2143C, 
T2182C, G2224A, C2245T, and T2289C [14,36,37]. 
It is also known that the prevalence of mutations in 
23S rDNA associated with clarithromycin-resistance 
varies in different parts of the world as follows: 48–
53% of isolates had an A2142G mutation, 39–45% 
an A2143G mutation, and up to 7% an A2142C mu-
tation in the USA [38,39]; 23–33% had an A2142G 
mutation, 44–67% an A2143G mutation, and 2–10% 
an A2142C mutation in Europe [40,41]; while the 
A2142C mutation was not detected, and more than 
90% of the mutant strains had an A2143G mutation 
in Japan [42]; the mutation A2143G occurred in 
100% of isolates in China [43]. In this study, we have 
characterized the 23S rRNA gene mutations of all 18 
clarithromycin-resistant isolates from Buddhist Tzu 
Chi General Hospital in Hualien. The most prevalent 
mutations were the T2182C (6/18; 33.3%) single 
mutation, which was identified in Korea [14], as well 
as the T2182C plus A2143G double point mutations 
(6/18; 33.3%). However, the dominant mutation is 
A2144G in western Taiwan [32]. Moreover, these 
mutations seem to be associated with high levels of 
clarithromycin resistance (≥ 256 μg/mL). In contrast, 
the A2143G single mutation, the major type of mu-
tation in Europe, the USA, Japan and China, exhibits 
a low prevalence (2/18; 11.1%) in our area [38–43]. 
Furthermore, there is evidence to suggest that a het-
erozygous condition exists in clarithromycin-resistant 
H. pylori, where one 23S rDNA allele is of the wild-
type genotype while the other copy is of the mutant 
genotype [9]. Stone et al indicated that two of 40 
clarithromycin-resistant isolates, one with a mutation 
at position 2143 and the other with a mutation at 
position 2144 in the 23S rDNA gene, were hetero-
zygous [39]. In this study, we also found that three of 
the eastern Taiwan isolates had heterozygous geno-
types. The most notable finding in our study is the 
C2227T single mutation, which is related to high clar-
ithromycin MICs and has not been reported elsewhere. 
The reason could be that the C2227T transition, which 
falls in a highly conserved region of the 23S rRNA as-
sociated with the functional site, domain V, has a 
strong effect on the secondary structure of the 23S 
RNA and with its interaction with macrolide [44]—
suggesting that the T-to-C transition at position 2717 
may be responsible for clarithromycin resistance.
A strong association between clarithromycin re-
sistance and the presence of iceA1, cagA and the 
vacAs1m2 allele has previously been reported 
[20–23]. However, we observed no significant asso-
ciation between clarithromycin resistance and the 
cagA gene, vacA allele mosaicism, and the iceA geno-
types in this study. To the best of our knowledge, 
there have been no other reports concerning the mu-
tation sites in clarithromycin-resistant strains and the 
association between drug resistance and the geno-
types of virulence factors in Taiwan.
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